Rationale, progress and development of vaccines utilizing STING-activating cyclic dinucleotide adjuvants - Wikidata - wikimedia - TriplyDB

Rationale, progress and development of vaccines utilizing STING-activating cyclic dinucleotide adjuvants

Rationale, progress and development of vaccines utilizing STING-activating cyclic dinucleotide adjuvants

http://www.wikidata.org/entity/Q27025822

about

STING: infection, inflammation and cancer Vaccines, Adjuvants, and Dendritic Cell Activators--Current Status and Future Challenges.Characterization of a Novel Human-Specific STING Agonist that Elicits Antiviral Activity Against Emerging Alphaviruses Intranasal immunization of pigs with porcine reproductive and respiratory syndrome virus-like particles plus 2', 3'-cGAMP VacciGrade™ adjuvant exacerbates viremia after virus challenge.DMXAA causes tumor site-specific vascular disruption in murine non-small cell lung cancer, and like the endogenous non-canonical cyclic dinucleotide STING agonist, 2'3'-cGAMP, induces M2 macrophage repolarization OASes and STING: adaptive evolution in concert Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity.Nanoparticulate STING agonists are potent lymph node-targeted vaccine adjuvants.STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade.TLR9 and STING agonists synergistically induce innate and adaptive type-II IFN.The Vaccine Adjuvant Chitosan Promotes Cellular Immunity via DNA Sensor cGAS-STING-Dependent Induction of Type I Interferons The STING controlled cytosolic-DNA activated innate immune pathway and microbial disease STING, nanoparticles, autoimmune disease and cancer: a novel paradigm for immunotherapy?Treatment of chronic hepatitis B with pattern recognition receptor agonists: Current status and potential for a cure Induction of tumor regression by intratumoral STING agonists combined with anti-programmed death-L1 blocking antibody in a preclinical squamous cell carcinoma model.Cancer Immunotherapy: Selected Targets and Small-Molecule Modulators.Agonist-Mediated Activation of STING Induces Apoptosis in Malignant B Cells.Listening to each other: Infectious disease and cancer immunology.Cyclic Dinucleotides in the Scope of the Mammalian Immune System.Sublingual targeting of STING with 3'3'-cGAMP promotes systemic and mucosal immunity against anthrax toxins.Dendritic cell therapy in melanoma.A STING Agonist Given with OX40 Receptor and PD-L1 Modulators Primes Immunity and Reduces Tumor Growth in Tolerized Mice.Stimulating Innate Immunity to Enhance Radiation Therapy-Induced Tumor Control.Identification and Characterization of Stimulator of Interferon Genes As a Robust Adjuvant Target for Early Life Immunization.Biodegradable STING agonist nanoparticles for enhanced cancer immunotherapy.A robust microparticle platform for a STING-targeted adjuvant that enhances both humoral and cellular immunity during vaccination.Therapeutic cancer vaccines.STING-Activating Adjuvants Elicit a Th17 Immune Response and Protect against Mycobacterium tuberculosis Infection.Small Molecules Drive Big Improvements in Immuno-Oncology Therapies.Chitosan Microsphere Used as an Effective System to Deliver a Linked Antigenic Peptides Vaccine Protect Mice Against Acute and Chronic Toxoplasmosis.STING agonists enable antiviral cross-talk between human cells and confer protection against genital herpes in mice.

P2860

Q26776009-1C9CFFB2-CE56-41DA-AA66-1B106CA9F588 Q26796314-0BD2556C-8B83-4A9D-94B9-57E9EE4B200E Q28551420-BC1B299B-3F01-4C0F-AD93-3693D012E980 Q33556636-7715077E-8318-471A-9CF0-7F0EAA7FFDAC Q33773787-EFD6B2EE-A1DA-4B93-8873-CE4C2F36A7B9 Q35569805-5D18FE4B-284D-45DD-92BE-C6B2B6A0183D Q35634752-9078AC90-7B4F-4582-B2A8-99F60E21258B Q35836140-B49BBBF5-EDAD-4D62-A658-1B25BA067204 Q35858368-D5C4D990-4000-4686-AF08-C275DE042EBE Q36350923-A3524A77-76DB-48B4-8300-A5EDD5788FFC Q36857386-CB24DEE1-89DE-421A-8081-9E7AC90A9579 Q38275607-7C423A0E-B41F-4E83-8D7F-1660CD94572F Q38293111-B4F9E68B-E737-47C9-9907-352B210BC54D Q38553065-00FBA8EE-BC30-4BC6-984C-0812D7C20ACB Q38711286-2B12E325-2847-4A46-865B-A7F26821C9D1 Q38719858-2301E3E5-638B-4206-9350-94B8BECBD69D Q38788154-AE6B2526-9AAE-45F8-B28C-8451F8089EC0 Q40103816-A86D232B-7F8E-45B2-BFB9-6EA10CD8DFDE Q40339226-A34D2544-1E4F-4647-BBFC-4C0E32B1B984 Q43170567-B35707BB-4616-4E93-AB52-6158D8068944 Q43923587-74DAFBD1-4E64-42E6-B6F1-BA44163CC383 Q46094829-3DEEF291-4F2C-4CE6-88DF-16E0C1138458 Q46189367-3BF67C5A-D185-46AE-845E-0BE6551C14BD Q47169865-1EA40889-73D7-478B-84A1-1D073E35E615 Q47359765-45621BE8-7E10-47E4-8CC3-54E92F2531A1 Q47573396-509474C1-34AF-4818-885A-0D489ABEA7B1 Q50988785-25E6D397-424F-4D74-96AB-67A9FDA6F06E Q52714689-B078EFC0-4E35-453B-A1F3-FBE5465CD23D Q53047113-2828A0EB-0EB7-4CE1-BF40-8489E34E23E4 Q55224227-3CCE18D0-B7D5-4207-9E36-21FC72A035E4 Q55399721-16B5DCBB-F934-4CC1-BB89-06C1EA696879

P2860

Rationale, progress and development of vaccines utilizing STING-activating cyclic dinucleotide adjuvants

http://www.wikidata.org/entity/Q27025822

description

2013 nî lūn-bûn

@nan

2013 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Rationale, progress and develo ...... cyclic dinucleotide adjuvants

@ast

Rationale, progress and develo ...... cyclic dinucleotide adjuvants

@en

Rationale, progress and develo ...... cyclic dinucleotide adjuvants

@nl

type

label

Rationale, progress and develo ...... cyclic dinucleotide adjuvants

@ast

Rationale, progress and develo ...... cyclic dinucleotide adjuvants

@en

Rationale, progress and develo ...... cyclic dinucleotide adjuvants

@nl

prefLabel

Rationale, progress and develo ...... cyclic dinucleotide adjuvants

@ast

Rationale, progress and develo ...... cyclic dinucleotide adjuvants

@en

Rationale, progress and develo ...... cyclic dinucleotide adjuvants

@nl

P1433

Q27025822-81B11FDC-6E79-45F8-ACF9-455117C5F834

P1476

Q27025822-E6DA659E-398D-4288-B543-E2CE75F3562D

P2093

Q27025822-8D5FD71D-32C0-4D46-B8B3-F5346A8D9BA2

Q27025822-CF7406C6-F6D0-42D5-9A5D-DE7903555F73

Q27025822-D8756EF6-F2A0-4333-A6C2-F9D16B8D6BEE

P2860

Q27025822-00D568DC-0455-488D-9956-E9F1EC322D10

Q27025822-015C1E15-7EFD-4790-9980-E73B7EE617FA

Q27025822-02934783-84C9-4381-9934-A02A27CB54A7

Q27025822-0403575E-7040-4289-8E78-D16CFEC97AD5

Q27025822-09ADE6A9-8953-4E2D-8CB8-F4793AE37551

Q27025822-1438C07F-90F9-497E-BA45-4D5412DBC270

Q27025822-1899AF29-C39C-4DB1-929C-6E43B0A82557

Q27025822-1B57ADE9-0B55-4A15-9C2A-CB1A6688E3ED

Q27025822-23E67C01-6A3A-4A4A-A985-661759F2B013

Q27025822-25C4220F-F0D7-4924-A0A4-00D42DF00776

P304

Q27025822-7B589A5E-91E6-44A6-B343-B7DDA5A564CB

P31

Q27025822-F11CF877-B6A8-46AB-8E7E-2CE6545BD9CB

P356

Q27025822-1697C5A1-96D6-41E8-B5D1-D3BC052B94D6

P407

Q27025822-D3BFE9D5-4D5B-44ED-8218-3247457C81AE

P433

Q27025822-D3181165-7AB4-4308-BE6B-E70500B5CFB4

P478

Q27025822-56D8ABEE-B805-4637-ADE7-2876313A00C9

P577

Q27025822-B3299D9C-46DC-4875-AE7C-853BC9CD1D75

P698

Q27025822-3F2E2F80-3DEF-4B2D-B3E2-A68902B9C304

P921

Q27025822-EFA772FE-2311-4872-B85A-411ED20D6175

P932

Q27025822-E9B07259-2D84-44C0-A64F-C59EE442F165

P356

2051013613501988

P1433

Therapeutic advances in vaccines

P1476

Rationale, progress and develo ...... cyclic dinucleotide adjuvants

@en

P2093

D. B. Kanne

http://www.w3.org/2001/XMLSchema#string

M. L. Leong

http://www.w3.org/2001/XMLSchema#string

T. W. Dubensky

http://www.w3.org/2001/XMLSchema#string

P2860

Evaluation of the sublingual route for administration of influenza H5N1 virosomes in combination with the bacterial second messenger c-di-GMP

Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway

STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling

c-di-AMP secreted by intracellular Listeria monocytogenes activates a host type I interferon response

Structure of STING bound to cyclic di-GMP reveals the mechanism of cyclic dinucleotide recognition by the immune system

STING is a direct innate immune sensor of cyclic di-GMP

A host type I interferon response is induced by cytosolic sensing of the bacterial second messenger cyclic-di-GMP

Cyclic di-GMP: the first 25 years of a universal bacterial second messenger

Cyclic [G(2′,5′)pA(3′,5′)p] Is the Metazoan Second Messenger Produced by DNA-Activated Cyclic GMP-AMP Synthase

Structure of Human cGAS Reveals a Conserved Family of Second-Messenger Enzymes in Innate Immunity

P304

131-43

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/2051013613501988

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

1

http://www.w3.org/2001/XMLSchema#string

P577

2013-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24757520

http://www.w3.org/2001/XMLSchema#string

P921

vaccine development

P932

3991150

http://www.w3.org/2001/XMLSchema#string